New study examines trends in liquid laundry detergent packet exposures among young children

Neu­roSense an­nounced sec­ondary end­point da­ta for its ALS treat­ment, which is a com­bi­na­tion of the an­tibi­ot­ic ciprofloxacin and the NSAID cele­cox­ib. In the Phase IIb

SAN DIEGO — As­traZeneca’s ex­per­i­men­tal PARP1 in­hibitor helped shrink tu­mors in near­ly half of peo­ple with breast can­cers har­bor­ing cer­tain DNA re­pair de­fects in an